drugset / Trial / NCT03619655
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Phase 1
Terminated
3 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
Outcome
Outcome not reported
Stopped: “Due to changing prostate cancer standard of care, the research question became obsolete as the target population for the study no longer existed. The study is deemed not clinically relevant.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 333 mbq | Intravenous |
| Subject | 18F-NaF | Diagnostic / imaging agent | 5 mbq | Intravenous |